While EGFR overexpression has correlated with disease progression in HNSCC [5, 6, 25], EGFR expression status did not predicts clinical outcomes in the RTOG 0522 trial of concurrent accelerated RT plus cisplatin with or without cetuximab [9]. The gene discussed is EGFR; the disease is head and neck squamous cell carcinoma.